Recombinant human PDCD5 protein enhances chemosensitivities of hematologic malignancies

Chinese Science Bulletin

Volumn 54, Issue 21, 2009, Pages 3981-3989

  Wang, YanFang ^a   Shi, Lin ^a   Song, QuanSheng ^b,c   Zhang, YingMei ^b,c   Lou, YaXin ^c   Zheng, Yi ^b,c   Ma, DaLong ^b,c   Wang, Ying ^b,c   Ke, XiaoYan ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Apoptosis; Chemosensitivity; Chemotherapy; Hematologic malignancies; PDCD5

Indexed keywords

MUS MUSCULUS;

EID: 71049119804     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-009-0635-z     Document Type: Article

References (45)

1. Dive C, Evans C A, Whetton A D. Induction of apoptosis - new targets for cancer chemotherapy. Semin Cancer Biol, 1992, 3: 417-427.
2. Hannun Y A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997, 89: 1845-1853.
3. Los M, Herr I, Friesen C, et al. Cross-resistance of CD95-and druginduced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 1997, 90: 3118-3129.
4. Filomenko R, Poirson-Bichat F, Billerey C, et al. Atypical Protein Kinase Cζ as a target for chemosensitization of tumor cells. Cancer Res, 2002, 62: 1815-1821.
5. Henson E S, Johnston J B, Gibson S B. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma, 2008, 49: 27-35.
6. Kim R, Eml M, Tanabe K, et al. Therapeutic potential of antisense Bcl-2 as a chemo-sensitizer for cancer therapy. Cancer, 2004, 101: 2491-2502.
7. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med, 2002, 8: 808-815.
8. Scappaticci F A, Contreras A, Smith R, et al. Statin-AE: A novel angiostatin-endostation fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis, 2001, 4: 263-268.
9. Plum S M, Hanson A D, Volker K M, et al. Synergistic activity of recombined human Endostatin in combination with Adriamycin: Analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res, 2003, 9: 4619-4626.
10. Liu H T, Wang Y, Zhang Y M, et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun, 1999, 254: 203-210.
11. Wang Y, Li X, Wang L, et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 over-expression. J Cell Sci, 2004, 117: 1525-1532.
12. Rui M, Chen Y Y, Zhang Y M, et al. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci, 2002, 71: 1771-1778.
13. Chen L N, Wang Y, Ma D L, et al. Short interfering RNA against the PDCD5 attenuates cell apoptosis and caspase-3 activity induced by Bax overexpression. Apoptosis, 2006, 11: 101-111.
14. Xu X R, Huang J, Xu Z G, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA, 2001, 98: 15089-15094.
15. Spinola M, Meyer P, Kammerer S, et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J Clin Oncol, 2006, 24: 1672-1678.
16. Yang Y H, Zhao M, Li W M, et al. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis, 2006, 11: 993-1001.
17. Tan W L, Xiong L, Zheng S B, et al. Relationship between programmed cell death 5 protein expression and prognosis of renal clear cell carcinoma (in Chinese). J Southern Med Univ, 2006, 26: 1316-1318.
18. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med, 2001, 344: 539-548.
19. Feng J, Cui H, Wei L H, et al. Expression of TFAR19 protein in epithelial ovarian cancer (in Chinese). Chin J Clin Obstet Gynecol, 2002, 3: 164-167.
20. Zhao X Y, Liu H W, Wei M J. Expressions of PDCD5 and p53 in oral leukoplakia and oral squamous cell carcinoma (in Chinese). J Peking Univ (Health Sci), 2005, 37: 429-432.
21. Liu Z H, Zhang D, Li K M, et al. Expression of PDCD5 in tissues of normal cervix, CIN I-III and cervical cancer (in Chinese). J Peking Univ (Health Sci), 2004, 36: 407-410.
22. Du Y, Hong T P. A preliminary study on the relationship between TF-1 cell apoptosis-related gene 19 and thyroid tumor (in Chinese). Chin J Intern Med, 2003, 42: 492-494.
23. Li H, Wang Q, Gao F, et al. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol Rep, 2008, 20: 573-579.
24. Ruan G R, Qin Y Z, Chen S S, et al. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res, 2006, 30: 1159-1165.
25. Ma X, Ruan G R, Wang Y, et al. Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5′ regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population. Clin Cancer Res, 2005, 11: 8592-8599.
26. Aye M T, Seguin J A, Mcburney J P. Erythroid and granulocytic colony growth cultures supplemented with human serum lipoproteins. J Cell Physiol, 1979, 99: 233-238.
27. Passioura T, Shen S, Symonds G, et al. A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells. Oncogene, 2005, 24: 7327-7336.
28. Jin C N, Wang Y, Han W L, et al. CMTM8 induces caspase-dependent and -independent apoptosis through a mitochondria-mediated pathway. J Cell Physiol, 2007, 211: 112-120.
29. Varvaresou A, Iakovou K, Gikas E, et al. Antitumor activity of imidazo-thioxanthones in murine and human tumor models in vitro and in vivo. Anticancer Res, 2004, 24: 907-919.
30. Wang N, Lu H S, Guan Z P, et al. Involvement of PDCD5 in the regulation of apoptosis in fibroblast-like synoviocytes of rheumatoid arthritis. Apoptosis, 2007, 12: 1433-1441.
31. Vaux D L, Korsmeyer S J. Cell death in development. Cell, 1999, 96: 245-254.
32. Hanahan D, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100: 57-70.
33. Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411: 342-348.
34. Laurent G, Jaffrezou J P. Signaling pathways activated by daunorubicin. Blood, 2001, 98: 913-924.
35. Solary E, Bertrand, R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma, 1994, 15: 21-32.
36. Chen G Q, Shi X G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of promyelocytic leukemia (APL): As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345-3353.
37. Kim C N, Wang X, Huang Y, et al. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res, 1997, 57: 3115-3120.
38. Ruan G R, Chen S S, Chang Y, et al. Adenovirus-mediated PDCD5 gene transfer sensitizes apoptosis of K562 cells induced by etoposide. J Exp Hematol, 2007, 15: 936-940.
39. Ruan G R, Zhao H S, Chang Y, et al. Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo. Apoptosis, 2008, 13: 641-648.
40. Wang Y, Li D, Fan H, et al. Cellular uptake of exogenous human PDCD5 protein. J Biol Chem, 2006, 281: 24803-24817.
41. Chen Y Y, Sun R H, Han W L, et al. Nuclear translocation of PDCD5 (TFAR19): An early signal for apoptosis? FEBS Lett, 2001, 509: 191-196.
42. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein resource interaction network: A resource for annotating the proteome. Cell, 2005, 122: 957-968.
43. Xu L J, Chen Y Y, Song Q S, et al. PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia, 2009, 11: 345-354.
44. Ozaki Ki, Kishikawa F, Tanaka M, et al. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci, 2008, 99: 376-384.
45. Keshelava N, Davicioni E, Wan Z S, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst, 2007, 99: 1107-1119.